Skip to main content

Table 1 Characteristics of healthy controls and enrolled HIV-1 infected cART-naive or long-term cART-treated patients in flow cytometry phenotyping

From: Activation-induced pyroptosis contributes to the loss of MAIT cells in chronic HIV-1 infected patients

Characteristic

HCs (n = 33)

ECs (n = 15)

TPs

CRs (n = 28)

INRs (n = 15)

CD4 ≥ 350

(n = 28)

CD4 < 350

(n = 41)

Age [years, M (Q1, Q3)]

29.0 (27.0, 35.5)

35.0 (29.0, 43.0)

28.5 (22.0, 40.0)

34.0 (27.0, 37.5)

25.0 (22.5, 31.5)

30.0 (24.8, 25.3)

Gender [male, n(%)]

18 (54.5)

12 (80.0)

23 (82.1)

33 (80.4)

26 (92.9)

14 (93.3)

CD4+ T cell counts [cells/µl, M (Q1, Q3)]

822.0 (684.0, 981.5)

627.0 (458.0, 741.0)

421.0 (374.3, 596.8)

194.0 (134.0, 277.5)

575.0 (506.5, 725.5)

155.0 (137.5, 178.0)

CD8+ T cell counts [cells/µl, M (Q1, Q3)]

621.0 (512.5, 765.0)

1026.0 (822.0, 1276.0)

1267.0 (1008.0, 1757.0)

1061.0 (676.0, 1335.0)

714.0 (558.5, 826.0)

694.5 (353.5, 893.5)

Plasma viral loads [× 104 copies/ml, M (Q1, Q3)]

NA

NA

15.8 (3.8, 56.9)

11.3 (4.2, 46.8)

 < LOD

 < LOD

cART regimen [n(%)]

 3TC/EFV/TDF

NA

NA

NA

NA

25 (89.2)

14 (93.3)

 3TC/LPV/TDF

NA

NA

NA

NA

2 (7.1)

1 (6.7)

 3TC/AZT/TDF

NA

NA

NA

NA

1 (3.6)

0

 3TC/DTG/TDF

NA

NA

NA

NA

0

1 (6.7)

cART duration time [month, M (Q1, Q3)]

NA

NA

NA

NA

42.9 (34.9, 65.8)

46.2 (35.4, 90.3)

  1. HIV human immunodeficiency virus, HCs healthy controls, ECs elite controllers, TPs treatment-naive patients, CRs complete responders, INRs immunological non-responders, NA not applicable, cART combined antiretroviral therapy, 3TC lamivudine, EFV efavirenz, TDF tenofovirdisoproxil, LPV lopinavir, AZT azidothymidine, DTG dolutegravir, < LOD below the limit of detection of 80 copies/ml